(Q36084912)

English

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial (English)

1 reference

Europe PubMed Central

12 August 2017

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Dona L Fleishaker

1

1 reference

Europe PubMed Central

12 August 2017

Juan A Garcia Meijide

2

1 reference

Europe PubMed Central

12 August 2017

Andriy Petrov

3

1 reference

Europe PubMed Central

12 August 2017

Michael David Kohen

4

1 reference

Europe PubMed Central

12 August 2017

Xin Wang

5

1 reference

Europe PubMed Central

12 August 2017

Sujatha Menon

6

1 reference

Europe PubMed Central

12 August 2017

Thomas C Stock

7

1 reference

Europe PubMed Central

12 August 2017

Charles A Mebus

8

1 reference

Europe PubMed Central

12 August 2017

James M Goodrich

9

1 reference

Europe PubMed Central

12 August 2017

Howard B Mayer

10

1 reference

Europe PubMed Central

12 August 2017

Bernhardt G Zeiher

11

1 reference

Europe PubMed Central

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 January 2012

1 reference

Europe PubMed Central

12 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

12 August 2017

14

1 reference

Europe PubMed Central

12 August 2017

1

1 reference

Europe PubMed Central

12 August 2017

R11

1 reference

Europe PubMed Central

12 August 2017

https://scigraph.springernature.com/pub.10.1186/ar3685

0 references

Maraviroc: pharmacokinetics and drug interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Amelioration of rat adjuvant-induced arthritis by Met-RANTES.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Over-ruling a group sequential boundary--a stopping rule versus a guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Chemokines as regulators of T cell differentiation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

2 October 2017

Endogenous glucocorticoids modulate neutrophil migration and synovial P-selectin but not neutrophil phagocytic or oxidative function in experimental arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

11 July 2018

CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

Trials of aplaviroc halted in treatment-naive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392799

23 September 2018

CXCR3 and CCR5 ligands in rheumatoid arthritis synovium

1 reference

https://pubmed.ncbi.nlm.nih.gov/22251436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective lymphocyte chemokine receptor expression in the rheumatoid joint

1 reference

https://pubmed.ncbi.nlm.nih.gov/22251436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22251436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22251436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of rheumatoid arthritis with a functional chemokine receptor, CCR5

1 reference

https://pubmed.ncbi.nlm.nih.gov/22251436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

12 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36084912&oldid=1635437591"